AGEN Agenus Inc: Forward P/S Multiple
Competition in immuno-oncology and a shortage of funds are weakening the defensive barriers of Agenus (AGEN). However, the automation of bioreactors and filling processes is reducing manual labor costs. The projected P/S ratio reflects market expectations, where the value is held at 2.30. This confirms Garo Armen's belief in the success of a broad drug portfolio and strategic alliances.
Agenus, Inc - analytical breakdowns and key metrics (AGEN)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
AGEN - Annual Net Income|Projected Future Earnings Agenus|AGEN - Market Cap to Earnings|Future Price to Earnings Agenus Inc|AGEN - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agenus, Inc|AGEN - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Agenus|AGEN - Earnings per share for the trailing year|Quarterly EPS earnings growth agenusbio.com|AGEN - Earnings growth in current year|Net earnings per share growth forecast for next year Agenus
- revenue and sales proceeds data:
Fundamental company analysis:AGEN (Agenus Inc.)
Searching for fundamental stability requires analyzing the ratio of market capitalization to projected revenue, which allows for an assessment of market expectations regarding future cash flows. The forward P/S dynamics of Agenus (AGEN) reflect investor sensitivity to sales scalability, considering the risks of dependence on external CMOs and CROs during the implementation of biotechnological developments, where sharp fluctuations in the curve signal a reassessment of commercialization potential.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|Projected Price to Revenue immunovant.com IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grifols SA GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Celldex Corp - Market Cap to Projected Revenue|Aurinia Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward P/S Multiple biocryst.com BCRX|VERA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|PHVS: Forward P/S Multiple|AbCellera Corp (ABCL) - Forward P/S Multiple|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|PGEN - Projected Price to Revenue|Forward P/S Multiple PHAR|NKTR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|ZBIO: Market Cap to Projected Revenue|IMNM - Price-to-Projected Revenue Ratio|Future Price to Revenue GOSS|KALV: Forward P/S Multiple|Septerna, Inc. - Forward Price to Sales|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward P/S Multiple Savara Pharma|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|ANAB (anaptysbio.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN - Forward Price-to-Revenue Multiple|RAPT Therapeutics, Inc. - Forward P/S Multiple|JBIO - Forward P/S Multiple|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|kyvernatx.com - Forward Price to Sales|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Forward Price-to-Revenue Multiple Theratechnologies, Inc THTX|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN - Forward Price-to-Revenue Multiple|CLYM: Forward Price-to-Revenue Multiple|ZURA - Forward P/S Multiple|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ADAG|IMA (ImageneBio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Shattuck Therapeutics STTK|Forward P/S Multiple EQ|Forward P/S Multiple connectbiopharm.com (CNTB)|Forward P/S Multiple IMUX (Immunic)|Projected Price to Revenue Atara Biotherapeutics, Inc.|InflaRx GmbH - Forward P/S Multiple|Market Cap to Future Revenue Ratio x4pharma.com|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CELU|Forward Price-to-Revenue Multiple INMB|Forward P/S Multiple Barinthus Biotherapeutics Corp|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|Market Cap to Expected Sales Ratio sabbiotherapeutics.com|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|Q32 Bio Corp - Forward P/S Multiple|Projected Price to Revenue GeoVax Corp (GOVX)|EDSA: Forward P/S Multiple|Market Cap to Future Revenue Ratio ibioinc.com (IBIO)|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Market Cap to Projected Revenue XTLB (XTL Biopharmaceuticals Ltd)|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|HCWB: Future Price to Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Forward Price to Sales AIM|Aditxt Corp - Forward P/S Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Vyome Therapeutics - Forward Price to Sales|Price-to-Projected Revenue Ratio Revelation Biosciences|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward P/S Multiple SCNI|Forward P/S Multiple calcimedica.com (CALI)|Affimed N.V. - Forward Price-to-Revenue Multiple|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward Price-to-Revenue Multiple Third Harmonic Bio Inc (THRD)
